Glaukos Corp. Hits New 52-Week High of $189.69, Up 67.65%

Glaukos Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 189.69 on August 13, 2026. This achievement marks a remarkable performance over the past year, with the stock appreciating by 67.65%, significantly outpacing the S&P 500's growth of 20.6% during the same period. The company's market capitalization stands at approximately USD 5,995 million, reflecting its position within the small-cap category. Despite being loss-making, Glaukos Corp. has shown resilience in its stock performance, with a notable price-to-book ratio of 9.14. The company currently does not offer a dividend, and its debt-to-equity ratio is reported at -0.42, indicating a unique financial structure. The stock's previous 52-week low was recorded at USD 73.16, highlighting the substantial upward movement it has experienced. This new high underscores Glaukos Corp.'s evolving market dynamics and its potential role within the biotechnology landscape.